Most Popular
-
1
'No Japan?' Korea swings from extreme rejection to selective embrace
-
2
National Assembly speeds up efforts to outlaw dog meat consumption in S. Korea
-
3
A man's constitutional battle reignites 'death with dignity' debate
-
4
S. Koreans' happiness rising slowly but surely: presidential panel
-
5
4 injured in rockfall at tourist attraction on eastern island of Ulleung
-
6
Races tighten in Seoul as parties battle for Assembly control
-
7
Heavy traffic jams on highways expected on 5th day of holiday
-
8
Seoul subway fare to rise 12% beginning Saturday
-
9
No. of depression patients exceeds 1m in 2022
-
10
US calls on China to encourage N. Korea's return to diplomacy
National Pension Service to file suit against Hanmi Pharmaceutical
By 김지현Published : Oct. 5, 2016 - 19:51
[THE INVESTOR] Korea’s National Pension Service, which holds a 10 percent stake in Hanmi Pharmaceutical, has decided to file for damages against the local pharmaceutical company should it be found to have been involved in irregularities.
“If the firm is discovered to have engaged in stock related irregularities that are penalized by the authorities, we will file the suit,” the world’s third-largest pension fund said in a statement.
The move comes as the Korea Exchange and financial authorities are investigating the drug maker for causing confusion among investors and causing unnecessary damages by belatedly disclosing that it has failed to export a third-generation cancer-fighting drug to Boehringer Ingelheim. The deal had been valued at 850 billion won (US$773.10 million).
Authorities suspect the information had been leaked to some of the investors—shortly before Hanmi stock prices plummeted.
By Kim Ji-hyun (jemmie@heraldcorp.com)
“If the firm is discovered to have engaged in stock related irregularities that are penalized by the authorities, we will file the suit,” the world’s third-largest pension fund said in a statement.
The move comes as the Korea Exchange and financial authorities are investigating the drug maker for causing confusion among investors and causing unnecessary damages by belatedly disclosing that it has failed to export a third-generation cancer-fighting drug to Boehringer Ingelheim. The deal had been valued at 850 billion won (US$773.10 million).
Authorities suspect the information had been leaked to some of the investors—shortly before Hanmi stock prices plummeted.
By Kim Ji-hyun (jemmie@heraldcorp.com)
![[Our Museums] Journey to the Paleolithic era at Jeongok Prehistory Museum](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=652&simg=/content/image/2023/10/03/20231003000137_0.jpg&u=20231003145607)
